MIRM Stock Up 16% after 7-Day Win Streak
Mirum Pharmaceuticals (MIRM) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 16% return. The company has gained about $598 Mil in value over the last 7 days, with its current market capitalization at about $3.8 Bil. The stock remains 82.7% above its value at the end of 2024. This compares with year-to-date returns of 10.5% for the S&P 500.
MIRM provides novel therapies for rare and orphan diseases, focusing on developing and commercializing investigational oral treatments like LIVMARLI for progressive familial intrahepatic cholestasis. After this rally, is MIRM still a buy – or is it time to lock in gains? Deep dive with Buy or Sell MIRM.
Comparing MIRM Stock Returns With The S&P 500
The following table summarizes the return for MIRM stock vs. the S&P 500 index over different periods, including the current streak:
- CrowdStrike Stock’s Surge Showed Up In Its Bookings Two Reports Early
- Fluor’s Profit Jump Was Borrowed From Its Own Second Half
- Palo Alto Networks Stock Ran On A Threat That Management Had Already Named
- GLOBALFOUNDRIES Stock Keeps Swinging Because Its Fastest Business Is Its Smallest
- NVIDIA’s Falling Multiple Is A Bill, Not A Bargain
- The Trade Desk Took Its Workloads In House, Then The Margin Guide Cracked
| Return Period | MIRM | S&P 500 |
|---|---|---|
| 1D | 1.2% | 0.3% |
| 7D (Current Streak) | 15.9% | 1.4% |
| 1M (21D) | 47.8% | 2.2% |
| 3M (63D) | 71.7% | 10.0% |
| YTD 2025 | 82.7% | 10.5% |
| 2024 | 40.1% | 23.3% |
| 2023 | 51.4% | 24.2% |
| 2022 | 22.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has MIRM behaved after prior drops? See MIRM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 73 S&P constituents with 3 days or more of consecutive gains and 38 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 52 | 7 |
| 4D | 3 | 30 |
| 5D | 13 | 1 |
| 6D | 3 | 0 |
| 7D or more | 2 | 0 |
| Total >=3 D | 73 | 38 |
Key Financials for Mirum Pharmaceuticals (MIRM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $186.4 Mil | $336.9 Mil |
| Operating Income | $-109.2 Mil | $-87.6 Mil |
| Net Income | $-163.4 Mil | $-87.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $111.6 Mil | $127.8 Mil |
| Operating Income | $-15.2 Mil | $-5.0 Mil |
| Net Income | $-14.7 Mil | $-5.9 Mil |
While MIRM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.